Sputtr.com | Alternative Search Engine

Astellas

Theravance and Astellas Announce the Commercial Launch of ...

Theravance and Astellas Announce the Commercial Launch of VIBATIV™ (telavancin) in the United States SOUTH SAN FRANCISCO, CA and DEERFIELD, IL - November 5, 2009 - Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV ™ (telavancin) in ...

Astellas Pharma Canada, Inc. - T he “Flying Star,” a ...

T he “Flying Star,” a beautiful shining star moving toward the future, depicts the Astellas brand. This symbol reflects the corporate vision of Astellas - to deliver hope and happiness to all for a healthy life, supported by leading edge science, technology and new insights.

Astellas Pharma US, Inc. Return Goods Policy Physicians and ...

Page 1 of 2 Astellas Pharma US, Inc. Return Goods Policy Physicians and Non-Hospital Clinics 1. Policy Scope This policy applies to physician practices and non-hospital based clinics that purchase Astellas products for

Astellas and APP Pharmaceuticals Announce Transfer of the ...

September 4, 2008 Astellas and APP Pharmaceuticals Announce Transfer of the Grand Island Plant Tokyo, Japan and Schaumburg, IL - September 4, 2008 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and APP Pharmaceuticals, Inc. ("APP"; Nasdaq: APPX ...

Astellas to Acquire Agensys, Inc.

November 27, 2007 Astellas to Acquire Agensys, Inc. Japan, November 27, 2007 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that its US subsidiary, Astellas US Holding, Inc. (headquarters: Deerfield, IL) has signed a definitive ...

Astellas Requestor’s Preliminary Review Checklist

Astellas Grant Office Notice on Grant Applications for Fellowship and Residency Support Astellas recognizes the importance of encouraging the training and development of fellows, residents, and other healthcare professional (HCP) trainees who have the potential to contribute to our understanding ...

Mundipharma Acquires EU / EEA Development and ...

FOR IMMEDIATE RELEASE Mundipharma Acquires EU / EEA Development and Commercialization Rights for Anti - Cancer Compound Bendamustine from Astellas Deutschland GmbH, Munich, Germany October 26 2006: Mundipharma International Corp. Ltd. (Mundipharma) , a privately held pharmaceutical company ...

Astellas-NovaQuest Alliance Establishes Market Leadership ...

Blockbuster Potential Unlocked Through Collaborative Teamwork How did Astellas' treatment for overactive bladder (OAB) become the number two brand in 2008?

TRAnSPlAnT ScholARS AwARd RUleS Kidney transplant,2006 TURN ...

Employees of Astellas Pharma US, Inc., its agencies, affiliates, and subsidiaries, and their respective family and household members, are not eligible for participation.

Lifecycle Management of the eCTD

• Advantages and disadvantages in submitting baselines Joerg Schnitzler,Head of Regulatory Operations, Astellas Pharma Europe B.V.,The Netherlands 17.30 Closing Remarks from the Chair and End of Day One Introduction This workshop is aimed at those who have never worked with the eCTD or